Pay in 4 interest-free payments of $6.64 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Retatrutide (development code LY3437943) is a 39-amino acid synthetic peptide developed by Eli Lilly as the first triple-receptor agonist targeting GLP-1R, GIPR, and GCGR in a single molecule
Research Use Only Disclaimer: This product is sold strictly for in vitro laboratory research
Safety Profile & Considerations Current understanding suggests: Generally well-tolerated in research settings No significant toxicity signals in preclinical studies Does not appear to suppress immune function However: Not approved for veterinary use Limited large-scale clinical trials in animals Should only be considered under qualified veterinary supervision What Veterinarians Are Observing In integrative and regenerative veterinary settings, BPC-157 is being explored as part of broader healing protocols
This placebo controlled study in 24 elderly individuals showed that a single dose of an NAD+ booster before exercise improved fatigue index, physical recovery and muscle function
Using such a product isn't just a waste of money
US$ 26.01
US$ 22.82
US$ 20.83
US$ 20.70
US$ 22.62
US$ 27.69
US$ 26.94
US$ 27.52
